Management of Sjögren's Syndrome

Initial Management

The initial management of Sjögren's syndrome should focus on symptom relief through a combination of topical therapies for sicca symptoms, with muscarinic agonists as first-line pharmacological treatment for patients with residual gland function, followed by targeted approaches for systemic manifestations if present 1, 2

For mild salivary gland dysfunction, begin with non-pharmacological stimulation including sugar-free gum and frequent sips of water 1
For severe salivary gland dysfunction with no salivary output, provide saliva substitution products 1, 2
First-line therapy for ocular dryness is artificial tears containing methylcellulose or hyaluronate at least twice daily 1
For persistent ocular dryness symptoms, consider autologous serum eye drops 1
Topical non-steroidal anti-inflammatory drugs and topical corticosteroids for inflammatory flares may be used for ocular dryness 3, 4

Evaluate for contributing conditions for fatigue and musculoskeletal pain 1, 2
For musculoskeletal pain, use analgesics according to pain severity following the WHO pain ladder 1
Consider short-term moderate-dose glucocorticoids for acute pain 1

Perform complete pulmonary function testing to assess severity of small airway disease 5, 1
Obtain high-resolution CT imaging with expiratory views for small airway disease 5
Treatment options for small airway disease include short course of systemic steroids, nebulized or inhaled bronchodilators and/or corticosteroids, and short course of empiric macrolide antibiotics 5
For symptomatic/moderate-severe interstitial lung disease, first-line treatment is systemic corticosteroids at 0.5-1.0 mg/kg 6
First-line maintenance for interstitial lung disease is mycophenolate mofetil or azathioprine as steroid-sparing agents 7, 6
Consider antifibrotic therapy with nintedanib as second-line maintenance for progressive fibrotic interstitial lung disease 1

For mild disease, use topical therapies and symptomatic management 3, 4
For moderate disease, consider short-term glucocorticoids at minimum effective dose and duration 1, 2
For severe disease, use glucocorticoids for initial control and immunosuppressive agents as steroid-sparing options 6, 7

Smoking cessation is strongly recommended for all Sjögren's patients 5
Ensure vaccination against influenza and pneumococcal infection 1
Avoid failing to distinguish between treatment of sicca symptoms versus systemic disease, prolonged use of glucocorticoids without appropriate steroid-sparing strategies, and overlooking potential side effects of immunosuppressive medications 2, 7, 6

The European League Against Rheumatism recommends beginning with non-pharmacological salivary stimulation using sugar-free gum, sugar-free acidic candies, or lozenges containing xylitol for patients with residual gland function, to manage xerostomia and oral symptoms 8
Systemic immunosuppressive therapy should be reserved for patients with active systemic disease affecting multiple organs, not for isolated GI symptoms, according to the European League Against Rheumatism 8

The American College of Chest Physicians recommends immediately investigating for lymphoproliferative disease in any patient presenting with unexplained weight loss, fevers, night sweats, or new/persistent lymphadenopathy, due to the 5-18% risk of developing lymphoma, particularly mucosa-associated lymphoid tissue (MALT) lymphoma 9
For severe systemic disease with GI involvement, the American College of Chest Physicians suggests using short-term moderate-dose glucocorticoids (0.5-1.0 mg/kg prednisone) followed by steroid-sparing agents like mycophenolate mofetil or azathioprine 9

Patients with Sjögren's syndrome should be monitored for lymphoma development, particularly in those with persistent parotid swelling, lymphadenopathy, or constitutional symptoms, as recommended by the American College of Chest Physicians 9